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Seventy-seven patients with ongoing acute rejec· 
tion on initial CsA therapy were converted to FK50S 
to attempt graft salvage. Fifty-nine patients had un· 
dergone primary transplantation and 18 had been reo 
transplanted; there were 52 cadaveric and 25 living· 
donor transplants. The indications for conversion to 
FKli06 were ongoing, biopsy-confirmed rejection in 
all patients, including vascular rejection in 20. The 
median interval to rescue was 2 months (range 2 
weeks to 36 months) after transplantation. Sixty-one 
of the 77 patients (79%) had already received one or 
more courses of an antilymphocyte preparation 
(OKT3: n=33; ALG or ATG: n=l; OKT3+ALG/ATG: 
n=27). Of the 77 patients, 57 (74%) have been success· 
fully rescued and still have functioning grafts with a 
mean follow-up of 14 months, with a mean serum cre-
atinine of 2.35±O.97 mg/dl. Eighteen patients were al-
ready dialysis-dependent at the time of conversion to 
FKli06; of these, 9 (500/0) were successfully salvaged 
and have a mean serum creatinine of 2.3 mg/dl. Of the 
61 patients previously treated with antilymphocyte 
preparations, 48 (79%) were rescued. In those sal-
vaged, prednisone doses have been lowered from 
22.2±7.2 mg/day preconversion to 7.5±5.S mg/day 
postconversion, and 12 patients are on FK506 mono-
therapy. In nondiabetics, mean serum glucose was 
101.4±20.5 mg/dl preconversion and 93.2±22 postcon· 
version (P=0.07), uric acid 7.3±2.3 and 7.1±1.5 mg/dl 
(P=O.53), and triglycerides 199.2±101.6 and 
IS7.2±106.4 mg/dl (P=O.06). Cholesterol levels were 
significantly lower following FK conversion 
(207.7±46.5 mg/dl pre. vs. 188.3±39.7 post., P=O.OO7). 
FKli06 is capable of salvaging renal allografts with 
ongoing acute rejection on CsA therapy, even when 
antilymphocyte preparations have been ineffective. 
Resistant allograft rejection under cyclosporine·based im~ 
munosuppression remains a considerable problem despite 
novel strategies designed to optimize the use of CsA, incIud-
ing sequential therapy with antilymphocyte preparations 
(1-5). Furthermore. the safety of steroid withdrawal under 
CsA immunosuppression and CsA monotherapy is unclear 
(6). The current modalities available to treat steroid· 
resistant rejection episodes under CsA·based immunosup-
pression are limited and may require retreatment with anti· 
lymphocyte regimens that have also been used for 
prophylaxis. These limitations often place the practitioner 
at a significant disadvantage when trying to achieve graft 
retention while sparing the recipient the morbidity associ-
ated with the intensive immunosuppression that accompa· 
nies most of these agents. Clearly, the development of novel 
antirejection agents that can be used to "rescue" grafts fail-
ing other standard protocols is needed. FK50S is an experi· 
mental immunosuppressive agent that has been used with 
encouraging results as primary therapy in renal transplan· 
tation (7). Steroid tapering and FK50S monotherapy can be 
achieved in a majority of patients with apparently no in· 
creased risk of rejection (8), which is usually not possible 
with CsA because of increased risk of rejection and nephro-
toxicity (1). We have recently begun to evaluate FK506 as a 
salvage agent for renal allografts failing conventional im· 
munosuppression under CsA. In a preliminary group of pa· 
tients we previously reported that FK506 cannot be used to 
salvage allografts with chronic rejection or CsA toxicity. but 
may hold promise for grafts with ongoing acute rejection 
(9). We now report our expanded experience with FK50S 
conversion of patients deemed to be losing their grafts from 
ongoing acute rejection while on CsA therapy. 
MATERIALS AND METHODS 
Patients. Between July 14, 1989 and February 16, 1993. seventy-
seven patients (44 male, 33 female) with a mean age of 33.3:!: 12.4 
years (range 2-59 years) were switched to FK506 immunosuppres. 
sion after failing CsA-based immunosuppression. Fifty-nine pa· 
tients (77%) were primary transplant recipients and 18 (23%) bad 
been retransplanted (12 second, 4 third, and 2 fourth transplants). 
1 Presented at the 19th Annual Meeting of the American Society of Fifty-two patients (68%) were recipients of cadaveric grafts and 25 
Transplant Surgeons, May 19-21, 1993, Houston, TX. (32%) were from living donors (21 related. 4 unrelated). Four pa-
2 Address correspondence to Mark L. Jordan, M.D., Suite 701, tients had received combined kidney-pancreas transplants. 1 pa· 
Liliane Kaufmann Building, 3471 Fifth Ave., Pittsburgh, PA 15213. tient was given a kidney and pancreatic islets. and 3 patients were 
J Division of Urologic Surgery and Renal Transplantation Univer- transplanted with pediatric "en bloc" kidneys from CAD donors un· 
sity of Pittsburgh Medical Center, Pittsburgh, PA 15213. der 24 months of age (JOt The causes of end-stage renal disease in-
• Pittsburgh Transplantation Institute. Department of Surgery, eluded glomerulonephritis in 20 patients. insulin-dependent melli-
University of Pittsburgh Medical Center. Pittsburgh, PA. tus in 14. renal hypoplasia/dysplasia in 5. adult polycystic kidney 
6 Division of Transplantation Pathology, University of Pittsburgh disease in 4. hypertension in 4, systemic lupus erythematosus in 4, 
School of Medicine. Pittsburgh, PA. focal segmental glomerulosclerosis in 2. posterior urethral valves in 
6 Department of Urologic Surgery, University of Bari. Bari, Italy. 2. and Alport's syndrome, Wegener's granulomatosis. calculous dis· 
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ease. medullary cystic disease. reflux nephropathy. tuberous sclero-
SIS. connective tissue disorder. and Lawrence Moon Biddell syn-
drome in 1 patient each. In 14 patients, the cause of ESRD 
was unknown. 
All 77 patients converted to FK506 had uncontrolled rejectIOn on 
primary CsA-based immunosuppressive therapy. The majority of 
the patients in this senes (64 of 77. 78%) were referred to our insti-
tution from other centers where they were deemed to be losmg their 
iITaft.s: 13 patients (22'7rl were entered from our own institUtion. 
Whenever possible. careful consideration was given to ensure that 
all patients had been maintained on m8X1mized but safe and toler-
able CsA dosing. Maintenance immunosuppression had consisted of 
CsA and prednisone m all patients. either with In=55. 71%) or 
without In=22. 29%) azathioprine. Previous antirejection therapy 
had been administered to all 77 patients in the form of bolus high-
dose corticosteroids. A total of 61 patients (79%) had also received 
at least 1 course of a monoclonal (OKT3l andlor polyclonal (ALG. 
ATG. or ATGAM) antilymphocyte preparation. Nineteen patients 
(25%) had received 2 or more courses of OKT3 prior to conversion 
and 27 patients (359'cl received OKT3 and a polyclonal antilympho-
cyte preparation prior to FK506. Of the 61 patients. only 5 had re-
ceived antilymphocyte prophylaxis alone without a subsequent 
course of either OKT3 or a polyclonal preparation to treat rejection 
pnor to FIG06. 
Protocol for FK506 conversion. Doppler ultrasound and radionu-
clide flow study of the allograft were performed in all cases to rule 
out a technical cause for allograft dysfunction prior to FK506 con-
version. In addition to reviewing pathologic specimens sent from 
the referring center. repeat core biopSies of the allograft were per-
formed in all patients at our institution as part of the evaluation for 
FIG06 conversion. Acute cellular rejection was present upon refer-
ral in all 77 cases, including 20 patients (26%) whose biopsies re-
vealed a vascular component of rejection <lymphocytic infiltration in 
arterial walls. intraglomerular hemorrhage. andlor infarction). All 
patients underwent a simple switch ("clean conversion") from CsA 
to FIG06 because of previous evidence of enhanced nephrotoxicity 
with combined FIG06 and CsA therapy in liver allograft recipients 
(11). FK506 was given at a standard daily oral dose of 0.3 mg/kgl 
day in divided doses every 12 hr starting 12 hr after the last CsA 
dose. Parental doses of FIG06 of 0.025 to 0.1 mg/kglday overlapping 
with the first 1 to 4 days of oral therapy were also given to 16 pa-
tients. Dosage adjustments were based upon monitoring of trough 
serum FK506 levels by ELISA (12) to achieve a 12-hr trough level 
of 1.0 to 2.0 ng/ml. and also by adjustment according to clinical and 
biochemical parameters. Data were analyzed for statistical signifi-
cance by paired two-tailed Student's t test or chi-square analysis 
when appropriate. 
RESULTS 
Seventy-seven patients failing primary CsA-based immu-
nosuppression with ongoing rejection were converted to 
FK506 at an average of 4.3=6.3 months (range 0.5 to 36 
months) following transplantation. The criteria for estab-
lishing successful graft salvage with FK506 included a re-
turn to or improvement in baseline serum creatinine 
(SCR),* and/or improvement on follow-up renal allograft bi-
opsy, and/or freedom from dialysis if the patient was 
dialysis-dependent at the time of conversion to FK506. With 
a mean follow-up of 13.9=9.1 months (range 2-34 months). 
57 of 77 patients (74%) have achieved graft salvage accord-
ing to the aforementioned criteria. All 77 patients converted 
to FK506 had evidence of ongoing cellular rejection on pre-
conversion allograft biopsy. Of these, 20 patients (26%) also 
had evidence of a vascular component of rejection, and 10 
• Abbreviations: PrLD, posttransplant lymphoproliferative dis-
ease; sea serum creatmine. 
patients (13%) converted to FK506 had never achieved ini-
tial graft function. The outcome of FK506 conversion in each 
of these groups is shown in Table 1. The best success was 
achieved in patients with elements of acute cellular reJec-
tion only on preconversion biopsy, with 40 of 47 (85'«) 
achieving graft salvage. Ten patients with grafts that had 
never functioned and who remained on dialysis from the 
time of transplantation were entered into this trial. An ad-
ditional 8 patients with primary graft function became 
dialysis-dependent as a result of severe ongoing rejection 
during initial CsA therapy before conversion to FK506. 
Overall. 18 of 77 patients (23%) were dialysis-dependent at 
the time of conversion to FK506. Nine of these patients 
(50%) currently have functioning grafts with a mean SCR of 
2.3= 1. 7 mg/dl at a mean follow-up of 18.4= 11.2 months 
(median 18 months) postconversion. 
Successful rescue with FK506 was obtained in 37 of 52 
(73%) CAD and in 20 of 25 (80%) LD recipients (P=NS). 
Sixty-four of the 77 patients were referred to our institution 
from outside centers for FK506 conversion; of these. 50 
(78%) were successfully rescued compared with 7 of 13 
(54%) entered from our own institution. Of 4 patients with 
combined kidney-pancreas transplants. 3 (75%) were res-
cued. Three patients were recipients of pediatric en bloc kid-
neys from CAD donors under 24 months of age; of these. 2 
(67%) were successfully salvaged. Equivalent success was 
obtained in the 59 primary transplantations (44 salvaged. 
74%) and the 18 retransplantations (13 salvaged, 72%). The 
time elapsed between transplantation and FK506 conver-
sion did not appear to influence the likelihood of success, as 
illustrated in Table 2. 
Preconversion immunosuppression and FK506 rescue. 
Prior to entry into the study, all 77 patients had been receiv-
ing esA-steroid based immunosuppression either with 
(n=55) or without (n=22) azathioprine. Those patients ini-
tially immunosuppressed with triple therapy (esA-steroids-
AZA) experienced significantly greater graft salvage (45155 
patients, 82%) than those initially on double therapy (12122 
patients, 55%) after FK506 conversion (P=O.03). Sixty of 
the 77 patients (78%) had failed at least one course of OKT3 
(average length of treatment 13.3:=6.2 days), and, of these. 
27 (45%) had also received induction antilymphocyte globu-
lin (ALG, ATG or ATGAM) (Table 3). Nineteen patients re-
ceived 2 or more courses of an antilymphocyte preparation; 
nine patients received 3 or more. In summary, of 61 patients 
failing preconversion antilymphocyte preparations, 48 (79%) 
were salvaged with FK506. The median interval between 
the last dose of the antilymphocyte preparation and initia-
tion of FK506 was 20 days (range 3 to 129 days). Although 
not statistically significantly different. the rate of successful 
conversion in patients previously treated with any antilym-
TABLE 1. Outcome of FIG06 conversion in 77 renal transplant 
patients failing pnmary CsA therapy 
Reason for conversion 
to FK506 
Acute cellular rejection only 
Cellular + vascular rejection 
Acute cellular rejection with 
primary nonfunction of allograft 
Thtal 
No. 
patients (%) 
47(61%) 
20(26%) 
10(13%) 
77 
No. successfully 
rescued (%) 
40(85%) 
13(65%) 
4(40%) 
57(74%) 
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TABLE 2. Effect of tlmmg of FK506 converSIOn followmg renal 
transplantation 
Interval between transplantatton No. No. I' 
and FK506 conversIOn (month" patIents ('; I S uccessfu I \ \; I 
:002 40 (52e;( I 28(70'1;' ) 
0.56 
>2 37 (480 I 29(78<;; ) 
:c: :} 55 (7Y; I 40(73e;( ) 
0.90 
>3 22 (29e;( I 17(77e;{ ) 
:006 66 (86e;(1 48(731),) 
0.79 
>6 11 (14'1, ) 9(82e;() 
TABLE 3. FK506 rescue therapy for ongoing rejection after 
antilymphocyte preparations" 
Type of antilymphocyte 
preparatIOn n Grafl salvage (C, I 
None 16 
OKT3 only 33 
ALG onlv 1 
OKT3 +'ALG/ATG/ATGAM 27 
TotaIIOKT3/ALG/ATG/ATGAM) 61 
9 
26 
1 
21 
48 
56e;( 
79% 
100% 
78o/r 
79'7r h 
o The median interval between last dose of antilymphocyte prepa-
ration and FK506 conversion was 20 days. 
h p = 0.13 compared with no antilymphocyte preparation. 
phocyte preparation was higher than those receiving none 
(P=0.13). 
Renal function before and after FK506 rescue. As de-
scribed above, 18 patients were dialysis-dependent at the 
time of FK506 switch: of these, 9 were successfully salvaged 
and became dialysis-independent. Of the remaining 59 pa-
tients not on dialysis at the time of conversion, 48 (80%) 
were rescued. The mean SCR prior to FK506 conversion in 
the successful switches was 3.2::: 1.6 mg/dL, excluding the 
nine patients who were on dialysis at the time of FK506 
conversion. The mean SCR after FK506 conversion was 
2.25:::0.87 mg/dl (P=0.002 vs. preconversion) for those pa-
tients not on dialysis at conversion and 2.35:::0.97 mg/dl 
(P=0.003 vs. preconversion) for all 57 patients with func-
tioning grafts (including the nine on dialysis at conversion), 
with a mean follow-up of 13.9:::9.1 months. Table 4 shows 
the time course of improvement in renal function following 
FK506 conversion. Overall, a statistically significant im-
provement in renal function was achieved within 4 weeks of 
conversion. For the 59 patients not on dialysis at the time of 
conversion, the preconversion median SCR was 3.0 mg/dl. 
Of 31 patients with an initial SCR :::;3 mg/dl, 25 (81 %) were 
successfully rescued compared with 23 of 29 patients (7917cl 
with initial SCR >3 mg/dl (P=0.85). Hence. the quality of 
initial renal function did not appear to correlate directly 
with the likelihood of successful rescue with FK506. 
Immunosuppression after FK506 rescue therapy. Prior to 
conversion from CsA to FK506. all patients were receiving 
steroid therapy. The average preconversion prednisone dose 
of 22.2:::7.2 mg/day has been lowered to 7.5:::5.6 mg/day, 
and 12 patients (21%) of the 57 with functioning grafts are 
currently on FK506 monotherapy (Table 5), Forty-seven of 
the 57 patients (82%) were also on AZA at the time of con-
version. Of these. 7 have had an increase in the AZA, 24 a 
decrease. 16 remain on the same AZA dose, and 17 have 
stopped AZA (Figure I), 
Biochemical parameters after FK506 rescue. In nondiabet-
ics. serum fasting glucose averaged 101.4:::20.5 mg/dl pre-
conversion and 93.2:::22.0 mg/dl postconversion (P=O.07l. 
Uric acid levels were 7.3:::2.3 mg/dl and 7.1:::1.5 mg/dl pre-
and postconversion, respectively, (P=O.53). Serum choles-
terol was significantly lower (207.7:::46.5 vs. 188.3:::39.7 mgl 
dl, P=0.007) postconversion. Triglycerides were 199.2:::101.6 
mg/dl pre- and 167.2::: 106.4 mg/dl postconversion. respec-
tively (P=0.061. 
Morbidity and mortality. There were six deaths, all occur-
ring in patients whose grafts had been lost. One patient 
died of overwhelming sepsis 1 month following conversion to 
FK506: on arrival from the referring center for conversion 
this patient had been found to be hypotensive and in respi-
ratory distress; intubation was required and the patient 
succumbed to pneumonia within 4 weeks. In retrospect, con-
version to FK506 in this patient was likely ill-advised. Two 
patients died of posttransplant Iymphoproliferative disease 
(PTLD) at 1 and 7 months postconversion, respectively. In 
the first case, the patient also had cytomegalovirus infec-
tion. Upon review of his allograft biopsy, the diagnosis of 
cellular rejection was thought to have been mistaken; the 
patient probably had PTLD of the allograft at the time of 
FK506 conversion. A fourth patient died of tuberculosis 3 
months following conversion. It was later discovered that 
this patient had been exposed to TB at the referring center 
prior to transfer to our institution for FK506 switch. A fifth 
patient died 4 months after conversion from a massive in-
tracranial hemorrhage, and a sixth patient died following 
return to dialysis 8 months after failing FK506 rescue. Ex-
cluding the patients who died. nineteen patients referred to 
us for FK conversion had prior complications, including 
CMV disease in 8, urine leak requiring surgical correction 
in 3, ureteral obstruction in 2, perforated duodenal ulcer fol-
TABLE 4. Renal function after conversion from CsA to FK506· 
Time after FK506 converS1On (weeks I 
0 
No. patients 48 48 
Mean SCR (mgldl :: SD) 3.20 == 1.6 3.20 :: 1.9 
Range 1.0--7.2 0.5-9.8 
P (vs. tlme Q) NAb 0.90 
Mean BUN (mgldl :: SOl 52.2 :: 31.0 55.4 ::': 33.5 
Range 12-154 14-149 
P (vs. tlme 0) NA 0.1 
a Excluding patients on dialysis at the time of conversIOn Ul FK506. 
b NA: not applicable. 
4 12 
48 43 
2.57 :: 1.1 2.39 == 0.9 
0.4-£.5 0.7-5.7 
0.003 0.003 
42.0 == 20.8 40.4 :: 18.6 
11-116 19--91 
0.05 0.03 
26 52 
32 20 
2.20 == 0.8 2.25 :: 0.9 
0.7-4.3 1.1-4.7 
0.004 0.002 
35.8 :: 13.2 35.3 :: 14.8 
16-58 16-57 
0.01 0.03 
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TABLE 5. Prednisone dose belore and after FK!iOb rescue 
Prednisone 
dose \ ml!ida~D I 
o 
1.25--2.5 
5 
7.5 
]() 
12.5 
15 
20 
>20 
Mean dose 
A. Prednisone 
No. pallen!..' I', ' 
---
PreconverslOn mo~trony"m~lln 
o (O'J;) 12 (21'; I 
o (Or;;) 417(', I 
0(0)<;; H (14"; I 
0(0'::' I 519'i I 
5 (9'7,.) 14 (25'; I 
1 (2(,( ) 6 (IO'i I 
3 (5'i; I 6110'i I 
29 (51<;; I 1 (2'.i I 
19 (33<;;) 1 12('i I 
22.2:= 7.2 7.5:= 5.6 
50 
• Preconverslon 
o Postconversion 
• • • • 40 • 
• 
30 • • • • • •• • 
• 
• 
o .' 
• 
20 --- _. 
0 
• 0 10 .0 0 0 0 00 
0 0 
0 ClDJO 0 
0 
0 10 20 
B. Imuran 
225 
200 
175 
150 0 
• 125 • 
100 0 
_ 0 
••• 
.... _ .. 
o 
• • 
o c. 
C [] CJt 
co co o. 
• • m • 
m 
m •• 0.0 
o 0 0 
o 
o 
30 40 50 
Patient' 
o • 
• oe 00 
o o 0 
CJt 0 • CJt «J 0 
75..:J • o. • 0 O.ClIO 
50 o. to • • o 0 • O. «:IJ 
25 o o 
60 
l~~wl<aKa~~rla~o-~~a<eur-~<o~----~ 
o 10 20 30 40 50 60 
Patient' 
FIGURE 1. Immunosuppression before and after FK506 conversion. 
(Al The average preconveraion prednisone dose of 22.2:=7.2 mg/day 
was lowered to 7.5:=5.6 mg/day, with 12 patients no longer taking 
prednisone. (B) Of 47 patients taking azathioprine at the time of 
conversion (mean dose 90.0:=37 mg/day), 7 have had a dose increase. 
24 a decrease. and 16 no change; 17 are no longer taking azathio· 
prine. For those still taking 8zathiopnne. the mean dose is 89 mg := 
4:3 mg/day. Patients 5. 16. 13. 14.24.25.32.35.39. and 47 were not 
taking azathioprine before or after conversion. 
lowing high-dose steroid therapy for rejection in 1. cutane-
ous herpesvirus infection in 1, Candida esophagitis in 1. 
lymphocele in 1. clostridium difficile colitis in 1, and renal 
artery stenosis requiring transluminal angioplasty in one. 
Fifteen of these patients (79", I were subsequentlv succe;;~­
fullv rescued v.;th FK506. There were Hi comphcations fol· 
lowing- FK506 conversion including- new onset diabetes mt'l-
htus in 4 patients E~ requiring" insulin. ~ controlled by oral 
medication I. CMV disease requiring g-anciclovlr therap~D 
In = 3 I. renal artery stenosis requiring" ang-ioplast~· 10 =- 21. 
epistaxis In = 1). bacterial pneumonia (n = 1 I. disease recur-
rence (membranoproliferatlVe g"lomerulonephritis. n = 11. 
and proteinuria (n= 1 I. None of these complicatIOns resulted 
in death. 
Rerejection and late failures atter FK50fi conversion. Two 
patients have reqUIred increases in immunosuppression for 
subsequent rejection episodes after FK506 conversion. all 
relatively late after rescue. One patient developed a mild 
rejection episode 19 months following" rescue (SCR increased 
from 2.8 to 3.4 mg/dl) and was treated with an increase in the 
prednisone dose (7.5 to 15 mg"lday J, and continues to do well. 
A second patient was given a bolus steroid treatment (1 g of 
methylprednisolone) 3 weeks after FK506 conversion for an 
increase in SCR from 2.2 to 2.7 mg/dl. and continues to do 
well at 9.5 months offollow-up on 17.5 mg of prednisone daily 
(SCR 2.3 mg/dll. One patient initially thought to have been 
salvag-ed from a vascular reJection by FK506 conversion (SCR 
decreased from 6.4 mg-/dl pre- to 2.1 mg/dl postconversion I 
has subsequently lost the waft and returned to dialysis :3 
months following conversion. 
DISCUSSION 
Since its introduction in the 1980s. CsA has become the 
mainstay of most immunosuppressive regimens in renal 
transplantation. Despite the development of novel treat-
ment strategies involving CsA. including sequential immu-
nosuppression following antilymphocyte preparation induc-
tion and combination therapy (1-6), certain disadvantages 
associated with its use have persisted. The incidence of re-
jection episodes utilizing even multiple drug" regimens based 
on CsA remains as high as 707r (1). Even with prophylactic 
antilymphocyte preparations in CsA-based regimens. 
steroid-resistant rejection episodes requiring additional or 
alternative antilymphocyte therapy occur with enough fre-
quency and severity to often result in overimmunosuppres-
sion and/or graft loss with attendant morbidity and mortal-
ity. An alternative agent to treat recalcitrant rejection 
episodes that have proved resistant to steroids and/or re-
treatment with antilymphocyte preparations would be an 
important addition to the therapeutic annamentarium. Sev-
eral promising "rescue" agents are currently in clinical tri-
als, including 15-deoxyspergualin 03. 1·1), RS-61443 US. 
16), and FK506 (7, 9). Phase I studies with deoxyspergualin 
for treatment of rejection have thus far been limited to pri-
mary rejection episodes and have thus far shown no advan-
tag"e over steroids (J./ l. The ability of deoxyspergualin to 
rescue grafts with steroid-resistant rejection has not yet 
been completely evaluated. A preliminary report of four 
patients suggests that deoxyspergualin may reverse reJec-
tion in some cases (17l. RS·61443 has shown promise as a 
potential rescue agent in a preliminary study of 72 patients 
with refractory rejection. of whom 55 (76%) responded (16). 
This experience with RS-61443 was. however. limited to 
first transplant recipients and no patients on dialysis were 
entered. 
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The use of FK506 as a primary aj!ent for immunosuppres-
sion in renal transplantation has yielded graft survival rates 
similar to those seen with CsA. but appears to have the 
advantage of permitting complete steroid withdrawal in up to 
60% of patients with no increased risk of rejection. The utility' 
of FK506 as a potential rescue agent for treating ongoing 
rejection has been previously reported by our group in a 
preliminary study of 24 patients in whom graft salvage was 
obtained in 71% (9). In that early expenence. it was deter-
mined that grafts with chronic rejection could not be salvaged 
by FK506. Since then. we have expanded our experience to 
include 77 patients with onj!oing acute rejection that form 
the basis of the current report. Graft salvage was obtained in 
74% of the cases. including 9 of 18 patients (50%) who were 
on dialysis at the time of conversion. 4 of 10 (40%) whose 
grafts had never functioned from the time of transplantation. 
and 48 of 61 (79%) who had received at least 1 course of an 
antilymphocyte preparation prior to FK506 conversion. The 
patient population included several risk factors-I8 retrans-
plants. 8 patients with CMV prior to rescue. and 3 patients 
with other infections. In the cases successfully rescued. fur-
ther decreases in steroid doses were achieved in 56 (98%) and 
prednisone was stopped completely in 12 (21%1. In only 2 
cases were further increases in steroid doses necessary after 
conversion (1 transiently, and subsequently tapered) and 
only 1 patient went on to lose the graft owing to rerejection 
after initial salvage with FK506. The pathologic severity of 
initial rejection did appear to influence the likelihood of suc-
cessful rescue with FK506 in that patients with cellular re-
jection only achieved an 85% response rate compared with 
65% of those with elements of vascular rejection. In rejecting 
kidneys that never functioned from the time of transplanta-
tion. however. 4 of 10 could be salvaged. This, taken together 
with the fact that 50% of patients already on dialysis at the 
time of conversion achieved salvage suggests that clinical 
parameters of graft function may not always be a reliable 
guide to predicting successful reversal of rejection with 
FK506. In fact. there was no difference in the rate of success-
ful rescue for patients with an initial SCR > 3 mgldl com-
pared with those with $3 mgidl (excluding patients on dialy-
sis at the time of switch). We hypothesized that another 
factor possibly influencing the likelihood of success was the 
interval between transplantation and the rescue attempt. 
However. we found no differences in the success rates 
whether FK506 conversion was performed before or after 2, 
3. or 6 months following transplantation. In most cases, renal 
function began to improve within 4 weeks following 
conversion-however. in 18 of the 57 successful switches 
(32%). SCR actually increased within 1 week of conversion 
before falling to baseline levels. This is most likely due to an 
element of transient nephrotoxicity induced by FK506 in the 
early postconversion period that resolved in all cases-and. 
in retrospect. may have been elemental in the efficacy of the 
rescue process. 
These data indicate that FK506 may possess a unique 
property as an "antirejection" drug, even though its basic 
mechanisms of action appear to be the same as those of CsA 
(18 l. aside from differences in potency. Properties other 
than inhibition of IL-2 and IL-4 synthesis (including sparing 
of IL-IO production in vitro) have recently been ascribed to 
FK506 (19). Further investigations may reveal by what 
mechanism FK506 may be able to reverse ongoing rejection. 
and these are underway In our laboratory. We are encour-
aged by our observations of clinical FK506 salvage therapy. 
and. based upon these results. an evaluation of the efficacy 
of FK506 as a first-line anti rejection drug in direct compari-
son with high-dose steroid therapy appears to be indicated. 
It is to be hoped that. as our experience with FK506 in-
creases. and as the results of ongomg multicenter dosing tri-
als accumulate. the optimum use of this promising drug in 
clinical renal transplantation will be further elucidated. 
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